Search Results - "Haj, Jelan I."

Kinome profiling identifies MARK3 and STK10 as potential therapeutic targets in uveal melanoma by Baqai, Usman, Kurimchak, Alison M., Trachtenberg, Isabella V., Purwin, Timothy J., Haj, Jelan I., Han, Anna, Luo, Kristine, Pachon, Nikole Fandino, Jeon, Angela, Chua, Vivian, Davies, Michael A., Gutkind, J. Silvio, Benovic, Jeffrey L., Duncan, James S., Aplin, Andrew E.

“…Most uveal melanoma cases harbor activating mutations in either GNAQ or GNA11. Despite activation of the mitogen-activated protein kinase (MAPK) signaling…”
Get full text

SOX10 Loss Sensitizes Melanoma Cells to Cytokine-Mediated Inflammatory Cell Death by Rosenbaum, Sheera R, Caksa, Signe, Stefanski, Casey D, Trachtenberg, Isabella V, Wilson, Haley P, Wilski, Nicole A, Ott, Connor A, Purwin, Timothy J, Haj, Jelan I, Pomante, Danielle, Kotas, Daniel, Chervoneva, Inna, Capparelli, Claudia, Aplin, Andrew E

“…The transcription factor, SOX10, plays an important role in the differentiation of neural crest precursors to the melanocytic lineage. Malignant transformation…”
Get more information

Slow proliferation of BAP1-deficient uveal melanoma cells is associated with reduced S6 signaling and resistance to nutrient stress by Chua, Vivian, Lopez-Anton, Melisa, Mizue Terai, Ryota Tanaka, Baqai, Usman, Purwin, Timothy J, Haj, Jelan I, Waltrich, Jr, Francis J, Trachtenberg, Isabella, Luo, Kristine, Tudi, Rohith, Jeon, Angela, Han, Anna, Chervoneva, Inna, Davies, Michael A, Aguirre-Ghiso, Julio A, Sato, Takami, Aplin, Andrew E

“…Uveal melanoma (UM) is the deadliest form of eye cancer in adults. Inactivating mutations and/or loss of expression of the gene encoding BRCA1-associated…”
Get more information

Abstract 6942: Single cell resolution of intrapatient drug resistance mechanisms in metastatic melanoma by Wilson, Haley P., Mersky, Glenn L., Haj, Jelan I., Teh, Jessica, Cheng, Phil F., Caksa, Signe, Stefanski, Casey D., Chua, Vivian, Capparelli, Claudia, Levesque, Mitch P., Dummer, Reinhard, Purwin, Timothy J., Aplin, Andrew E.

“…Intrapatient heterogeneity among different metastatic sites contributes to immunotherapy (ICi) and targeted therapy resistance. Determining the evolution of…”
Get full text

Abstract C048: Intrapatient heterogeneity and targeting microenvironment protection mechanisms in melanoma metastasis by Wilson, Haley P., Mersky, Glenn L., Haj, Jelan I., Teh, Jessica L.F., Cheng, Phil F., Caksa, Signe, Mustafa, Manal, Trachtenberg, Isabella, Waltrich, Francis J., Stefanski, Casey D., Chua, Vivian, Erkes, Dan A., Levesque, Mitchell P., Dummer, Reinhard, Purwin, Timothy J., Capparelli, Claudia, Aplin, Andrew E.

“…Intrapatient tumor heterogeneity contributes to immunotherapy and targeted therapy resistance in cutaneous metastatic melanoma patients. More than 50% of…”
Get full text